TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22956195
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (reference compound)
Study: 22956195
Drug: Relative bioavailability
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative bioavailability of FAP and FPP compared to ferrous sulfate
Study: 21381017
Drug: 5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg/kg daily G‐CSF
Study: 21381017
Drug: 10 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/kg daily G‐CSF
Study: 19298563
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (OPT)
Study: 12953125
Drug: (131)I-M195 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I-M195 or (131)I-HuM195 (122-437 mCi) plus busulfan (16 mg/kg) and cyclophosphamide (90-120 mg/kg)
Study: 10711488
Drug: Medium-size self-inflatable
Normalized name: febantel
DrugBank: Febantel (DB11409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-size self-inflatable bag (maximum volume, 1100 ml)
Study: 8622323
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (50 mg/kg intravenously)
Study: 8622323
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (50 mg/kg intravenously) in children with cyanosis
Study: 1419816
Drug: AMSA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMSA (100 mg/m2/d on days 7, 8, and 9)
Study: 2413835
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further chemotherapy
Study: 1419816
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (ara-C) (2-3 g/m2/12 h for 6 days)
Study: 6366660
Drug: High-dose prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prostaglandin E2 vaginal pessaries (3 mg)
Study: 6366660
Drug: Low-dose prostaglandin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prostaglandin E2 vaginal pessaries (0.5 mg)
Study: 31790418
Drug: Traditional first-line
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional first-line drugs
Study: 23351460
Drug: Bilirubin level
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilirubin level ≤0.6 mg/dl (group 1)
Study: 23351460
Drug: Bilirubin level
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilirubin level >0.6 to 1.2 mg/dl (group 2)
Study: 23351460
Drug: Bilirubin level
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilirubin level >1.2 mg/dl (group 3)
Study: 19690413
Drug: Milk supplemented
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplemented with Lactobacillus rhamnosus LB21 (10(7) CFU/ml) and 2.5 mg fluoride per litre for lunch
Study: 11703224
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (LDT)
Study: 7960489
Drug: Thiamine treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine treatment, 200 mg per day for 7 days
Study: 2958400
Drug: 2.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 micrograms Hevac B vaccine at birth, 1, 2 and 14 months (Group I)
Study: 2958400
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms Hevac B vaccine at birth, 2 and 14 months (Group II)
Study: 2958400
Drug: 2.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 micrograms Hevac B vaccine (Group I)
Study: 2958400
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms Hevac B vaccine (Group II)
Study: 29701040
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy at the points detected with thermosensitive moxibustion in Zhuang medicine combined with western medication (methotrexate, salazosulfapyridine, hydroxychloroquine, meloxicam)
Study: 29701040
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (methotrexate, salazosulfapyridine, hydroxychloroquine, meloxicam)
Study: 19035084
Drug: Novel analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel analgesic disposable Foley urinary catheter
Study: 3466574
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPI) 60 mg/m2
Study: 3466574
Drug: Doxorubicin (DX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DX) 40 mg/m2
Study: 25038794
Drug: Antibiotic alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic alone (Group A)
Study: 25038794
Drug: Antibiotic plus
Normalized name: Triple Antibiotic Plus
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic plus supplement (Group B)
Study: 20390374
Drug: Bioenterics‐BIB® (saline-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioenterics‐BIB® (saline-filled balloon, 700 ml)
Study: 18216054
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy 160/4.5 microg twice daily and as needed
Study: 15705992
Drug: Bronchodilator inhalation
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator inhalation (400 mug salbutamol by metered-dose inhaler)
Study: 15705992
Drug: Bronchodilator inhalation
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator inhalation
Study: 8911239
Drug: H2 blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2 blockers
Study: 1588630
Drug: High-dosage methylprednisolone
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage methylprednisolone administered within 8 hours after injury
Study: 9832286
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g intravenously every 8 h)
Study: 3890730
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g intravenously every 8 h) + Piperacillin
Study: 3890730
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g intravenously every 8 h) + Tobramycin
Study: 22995632
Drug: Maudsley Model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA)
Study: 27061709
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (SSCM and MANTRA)
Study: 20367114
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg IM dexketoprofen trometamol
Study: 20367114
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg IM diclofenac sodium
Study: 18630534
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy (TCM plaster sticking at Zhongwan (CV 12), Guanyuan (CV 4), Qihai (CV 6))
Study: 18630534
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (simple acupuncture at Zhongji (CV 3), Guanyuan (CV 4), Qihai (CV 6))
Study: 16060181
Drug: Stapled rectal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stapled rectal prolapse mucosectomy
Study: 1974401
Drug: Cetirizine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 10 mg once daily
Study: 1826243
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin (human ultralente insulin, n = 16)
Study: 1826243
Drug: Preprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preprandial insulin (human unmodified insulin, n = 19)
Study: 6347356
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) alone, 70 mg/m2
Study: 6347356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cisplatin (DDP) and cyclophosphamide, initial dose of cyclophosphamide 750 mg/m2
Study: 6347356
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) alone vs Combination therapy
Study: 29536332
Drug: Irradiation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation at a standard dose of 50 Gy in 25 fractions
Study: 29536332
Drug: Irradiation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation at a dose of 40.3 Gy in 13 fractions
Study: 22480803
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d duloxetine
Study: 22480803
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d duloxetine
Study: 20479938
Drug: HIV‐1 DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐1 DNA vaccine (VRC‐HVDNA 009‐00‐VP)
Study: 12403738
Drug: Twice-weekly exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly exercise class
Study: 8846840
Drug: 100% O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% O2 inhalation for 10 min
Study: 8846840
Drug: 5% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% CO2 with air inhalation for 10 min
Study: 2113543
Drug: Flumazenil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (up to 1.0 mg)
Study: 2113543
Drug: Flumazenil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (up to 2.0 mg)
Study: 2113543
Drug: Flumazenil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (up to 1.0 mg after placebo)
Study: 31303595
Drug: Antiviral (oseltamivir)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiviral (oseltamivir) alone
Study: 31303595
Drug: Antiviral (oseltamivir)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiviral (oseltamivir) in combination with antibiotic
Study: 25813217
Drug: Avibactam 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avibactam 50, 100, 250, 500, 1000, 1500 or 2000 mg as a 30-min intravenous infusion (single ascending dose)
Study: 25813217
Drug: Avibactam 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avibactam 250 mg with ceftazidime 1000 mg; Avibactam 500 mg with ceftazidime 2000 mg (second dose after washout)
Study: 25813217
Drug: Avibactam 500,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avibactam 500, 750 or 1000 mg every 8 h over 5 days (multiple ascending doses)
Study: 25813217
Drug: Ceftazidime-avibactam 2000-500
Normalized name: avibactam
DrugBank: Avibactam (DB09060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime-avibactam 2000-500 mg q8 h over 10 days
Study: 25813217
Drug: Avibactam 500
Normalized name: avibactam 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avibactam 500 mg (single oral dose)
Study: 23660319
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + E (levodopa + entacapone)
Study: 23660319
Drug: L (levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: L (levodopa alone)
Study: 23660319
Drug: L(−) (never
Approvals — FDA: no, EMA: no, PMDA: no
Description: L(−) (never on levodopa)
Study: 30758329
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg CBD
Study: 19587369
Drug: Abnormal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abnormal insulin resistance
Study: 19587369
Drug: Abnormal DeltaI/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormal DeltaI/G
Study: 19587369
Drug: Normal beta-cell
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal beta-cell function with improved insulin sensitivity
Study: 19587369
Drug: Deterioration in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deterioration in both insulin resistance and beta-cell function
Study: 9817300
Drug: Post-chemotherapy resection
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-chemotherapy resection for residual masses
Study: 7875419
Drug: Enprostil (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil (35 micrograms, twice a day)
Study: 10716135
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg once daily
Study: 28994661
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (120,000 IU/month)
Study: 28994661
Drug: Moderate-dose vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose vitamin D3 (60,000 IU/month)
Study: 28994661
Drug: Standard-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose vitamin D3 (18,000 IU/month)
Study: 26336883
Drug: Wii bowling
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Wii bowling intervention, played twice weekly for 6 weeks
Study: 11177333
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin treatment before each meal plus a bedtime injection of ultralente insulin
Study: 11177333
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin treatment
Study: 7712374
Drug: Moist ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moist ointment
Study: 3331039
Drug: Imipenem/cilastatin 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 1 g q 8 h
Study: 3331039
Drug: Aminoglycoside (tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside (tobramycin or netilmicin) plus amoxicillin 2 g q 8 h plus clindamycin 0.6 g q 6 h
Study: 30146969
Drug: Restrictive red‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive red‐cell transfusion strategy (transfusion if hemoglobin <7.5 g/dL)
Study: 30146969
Drug: Liberal red‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal red‐cell transfusion strategy (transfusion if hemoglobin <9.5 g/dL in ICU or <8.5 g/dL in non-ICU)
Study: 20462392
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg montelukast (MK)
Study: 16042665
Drug: GPI 5693
Normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPI 5693 1125 mg
Study: 16042665
Drug: GPI 5693
Normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPI 5693 300 mg
Study: 16042665
Drug: GPI 5693
Normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPI 5693 750 mg
Study: 16042665
Drug: GPI 5693
Normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPI 5693 with food intake (750 mg and 1125 mg)
Study: 16042665
Drug: GPI 5693
Normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPI 5693 300 mg, 750 mg, and 1125 mg
Study: 10467215
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication (specifics not provided)
Study: 7762265
Drug: DPT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT and PRP-T vaccines mixed in one syringe (n = 183)
Study: 7762265
Drug: DPT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT and PRP-T vaccines administered separately in opposite limbs (n = 184)
Study: 7762265
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (combined and separate injections)
Study: 2281031
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of a diclofenac sodium aqueous buffered solution
Study: 2281031
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg Voltaren EC tablet
Study: 2281031
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Voltaren slow-release (SR) tablet
Study: 26028546
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo transdermal patches)
Study: 15145965
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg oral dose
Study: 9588639
Drug: Oral desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral desmopressin (DDAVP) 400 mg
Study: 7976440
Drug: Religious psychotherapy
Normalized name: red delicious apple allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Religious psychotherapy in addition to supportive psychotherapy and anxiolytic drugs
Study: 7976440
Drug: Supportive psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive psychotherapy and anxiolytic drugs only
Study: 29724155
Drug: Nerve Growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve Growth Factor (NGF) treatment
Study: 24886512
Drug: Everolimus treatment
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus treatment
Study: 26185263
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose isotonic sodium bicarbonate (target 2.0 mEq/kg)
Study: 19843798
Drug: IV pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV pentazocine 15 mg
Study: 17374663
Drug: 0.7 g
Normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g DHA/d as a purified algal derived triacylglycerol (1.5 g/d)
Study: 17374663
Drug: Placebo (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.5 g olive oil/d)
Study: 15066683
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment at baseline
Study: 15066683
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment after 2 years of cumulative treatment
Study: 9399278
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy for the paretic upper extremity (10 min. of therapy at similar time intervals)
Study: 8178915
Drug: Casting for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casting for 1 month followed by traditional therapy for 1 month
Study: 8178915
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy for 1 month followed by casting for 1 month
Study: 1876282
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acid infusion
Study: 3295362
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (20 mEq/day) for three days before amino acid infusions
Study: 10714729
Drug: Methadone Maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone Maintenance Therapy (MMT)
Study: 27007583
Drug: Buprenorphine Maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine Maintenance Therapy (BMT)
Study: 20679179
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg/day for 5 days)
Study: 20679179
Drug: Sitagliptin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin with 0 mg enalapril
Study: 20679179
Drug: Sitagliptin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin with 5 mg enalapril
Study: 20679179
Drug: Sitagliptin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin with 10 mg enalapril
Study: 20679179
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg enalapril during sitagliptin
Study: 20679179
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg or 5 mg enalapril
Study: 18709692
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day for 4 months
Study: 14674497
Drug: Phosphoric acid
Normalized name: Phosphoric Acid
DrugBank: Phosphoric acid (DB09394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phosphoric acid treatment with Prime & Bond NT on enamel surfaces treated with 27-microm air-particle abrasion
Study: 14674497
Drug: Phosphoric acid
Normalized name: Phosphoric Acid
DrugBank: Phosphoric acid (DB09394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phosphoric acid treatment with Prime & Bond NT on enamel surfaces not treated with air-particle abrasion (control)
Study: 7767525
Drug: Theophylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300 mg twice a day)
Study: 2191443
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d oral fluconazole
Study: 2191443
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d ketoconazole
Study: 2191443
Drug: IV fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV fluconazole 100 to 300 mg/d
Study: 31381020
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (2400 IU/d; N = 315)
Study: 31381020
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose vitamin D3 (400 IU/d; N = 308)
Study: 26400188
Drug: Berberine hydrochloride
Normalized name: Berberine Hydrochloride
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine hydrochloride 400 mg, delivered twice daily for 8 weeks
Study: 23706111
Drug: Guaranà 350
Normalized name: GUARANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaranà 350 mg × 3 daily just after breakfast for 5 consecutive days
Study: 19583072
Drug: WHO Analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO Analgesic Ladder